Evidence map›Paper›PMID 37101029›Full record

ArticleWiener klinische Wochenschrift2023

[Obesity and type 2 diabetes (Update 2023)].

Martin Clodi, Hermann Toplak, Michael Resl, Johanna Brix, Deborah Raphaela Leitner, Jürgen Harreiter, Friedrich Hoppichler, Thomas C Wascher, Karin Schindler, Bernhard Ludvik

Open access · hybridAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Vitamin D Alleviates Type 2 Diabetes Mellitus by Mitigating Oxidative Stress-Induced Pancreatic β-Cell Impairment.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Martin ClodiAbteilung für Innere Medizin, Konventhospital der Barmherzigen Brüder Linz, 4021, Linz, Österreich. martin.clodi@jku.at.
Hermann ToplakKlinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich.
Michael ReslAbteilung für Innere Medizin, Konventhospital der Barmherzigen Brüder Linz, 4021, Linz, Österreich.
Johanna BrixMedizinische Abteilung mit Diabetologie, Endokrinologie und Nephrologie, Krankenanstalt Rudolfstiftung, Wien, Österreich.
Deborah Raphaela LeitnerKlinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich.
Jürgen HarreiterGender Medicine Unit, Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
Friedrich HoppichlerAbteilung für Innere Medizin, Krankenhaus der Barmherzigen Brüder Salzburg, Salzburg, Österreich.
Thomas C Wascher1. Medizinische Abteilung, Hanuschkrankenhaus, Wien, Österreich.
Karin SchindlerUniversitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
Bernhard LudvikMedizinische Abteilung mit Diabetologie, Endokrinologie und Nephrologie, Krankenanstalt Rudolfstiftung, Wien, Österreich.
Krankenanstalt Rudolfstiftung der Stadt Wien · ATMedical University of Graz · ATMedical University of Vienna · ATConvent Hospital of the Brothers of Saint John of God · ATHanusch Hospital · ATJohannes Kepler University of Linz · ATOrdensklinikum Linz Barmherzige Schwestern · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e.g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and additional concomitant therapies is increasingly influenced by body weight. The importance of modern GLP‑1 agonists and dual GLP‑1 GIP agonists increases since these drugs target obesity and type 2 diabetes. Bariatric surgery is at present indicated with a BMI > 35 kg/m

Indexed as

Diabetes Mellitus, Type 2Body CompositionBody Mass IndexBody WeightGlucagon-Like Peptide 1HumansObesityGlucagon-Like Peptide 1Body compositionFormula dietsNutritionObesityType 2 diabetes

Identifiers

PMID37101029
PMCPMC10133053
OpenAlexW4367165041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.